WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors

Zsófia Ujj, Gergely Buglyó, M. Udvardy, Dániel Beyer, György Vargha, Sándor Biró, László Rejtő

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Expression of the gene Wilms tumor 1 (WT1) has been suggested as a marker of minimal residual disease in acute myeloid leukemia (AML), but literature data are not without controversy. Our aim was to assess the presence, magnitude and temporal changes of WT1 expression as prognostic factors. 60 AML patients were followed until death or the end of the 6-year observation period. Blood samples were taken at diagnosis, post-induction, during remission and in case of a relapse. Using quantitative real-time PCR, we determined WT1 expression from each sample, normalized it against the endogenous control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and classified samples as negative, moderately positive or highly positive. We divided the patients into groups based on detected WT1 expression values, illustrated overall and disease-free survival on Kaplan-Meier curves, and compared differences between each group by the logrank test. Disappearance of WT1-positivity during chemotherapy had a favorable effect on survival. Interestingly, no difference was seen between the survivals of WT1-positive subgroups that expressed moderate or high levels of WT1 mRNA. A 1-log decrease in WT1 expression without becoming negative did not affect prognosis, either. Our results suggest that defining a cut-off value for WT1-positivity, rather than just using logarithmic figures of changes in gene expression, might have prognostic use in post-induction AML patients. We encourage further, larger-scale studies.

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalPathology and Oncology Research
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Wilms Tumor
Acute Myeloid Leukemia
Gene Expression
Remission Induction
Glyceraldehyde-3-Phosphate Dehydrogenases
Survival
Residual Neoplasm
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Observation
Recurrence
Drug Therapy
Messenger RNA

Keywords

  • Acute myeloid leukemia
  • Overexpression
  • Quantitative real-time PCR
  • WT1 gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

WT1 Expression in Adult Acute Myeloid Leukemia : Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors. / Ujj, Zsófia; Buglyó, Gergely; Udvardy, M.; Beyer, Dániel; Vargha, György; Biró, Sándor; Rejtő, László.

In: Pathology and Oncology Research, Vol. 22, No. 1, 01.01.2016, p. 217-221.

Research output: Contribution to journalArticle

Ujj, Zsófia ; Buglyó, Gergely ; Udvardy, M. ; Beyer, Dániel ; Vargha, György ; Biró, Sándor ; Rejtő, László. / WT1 Expression in Adult Acute Myeloid Leukemia : Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors. In: Pathology and Oncology Research. 2016 ; Vol. 22, No. 1. pp. 217-221.
@article{2e2fe4ddee364d9799cf802a52c9a542,
title = "WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors",
abstract = "Expression of the gene Wilms tumor 1 (WT1) has been suggested as a marker of minimal residual disease in acute myeloid leukemia (AML), but literature data are not without controversy. Our aim was to assess the presence, magnitude and temporal changes of WT1 expression as prognostic factors. 60 AML patients were followed until death or the end of the 6-year observation period. Blood samples were taken at diagnosis, post-induction, during remission and in case of a relapse. Using quantitative real-time PCR, we determined WT1 expression from each sample, normalized it against the endogenous control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and classified samples as negative, moderately positive or highly positive. We divided the patients into groups based on detected WT1 expression values, illustrated overall and disease-free survival on Kaplan-Meier curves, and compared differences between each group by the logrank test. Disappearance of WT1-positivity during chemotherapy had a favorable effect on survival. Interestingly, no difference was seen between the survivals of WT1-positive subgroups that expressed moderate or high levels of WT1 mRNA. A 1-log decrease in WT1 expression without becoming negative did not affect prognosis, either. Our results suggest that defining a cut-off value for WT1-positivity, rather than just using logarithmic figures of changes in gene expression, might have prognostic use in post-induction AML patients. We encourage further, larger-scale studies.",
keywords = "Acute myeloid leukemia, Overexpression, Quantitative real-time PCR, WT1 gene",
author = "Zs{\'o}fia Ujj and Gergely Bugly{\'o} and M. Udvardy and D{\'a}niel Beyer and Gy{\"o}rgy Vargha and S{\'a}ndor Bir{\'o} and L{\'a}szl{\'o} Rejtő",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s12253-015-0002-0",
language = "English",
volume = "22",
pages = "217--221",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - WT1 Expression in Adult Acute Myeloid Leukemia

T2 - Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors

AU - Ujj, Zsófia

AU - Buglyó, Gergely

AU - Udvardy, M.

AU - Beyer, Dániel

AU - Vargha, György

AU - Biró, Sándor

AU - Rejtő, László

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Expression of the gene Wilms tumor 1 (WT1) has been suggested as a marker of minimal residual disease in acute myeloid leukemia (AML), but literature data are not without controversy. Our aim was to assess the presence, magnitude and temporal changes of WT1 expression as prognostic factors. 60 AML patients were followed until death or the end of the 6-year observation period. Blood samples were taken at diagnosis, post-induction, during remission and in case of a relapse. Using quantitative real-time PCR, we determined WT1 expression from each sample, normalized it against the endogenous control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and classified samples as negative, moderately positive or highly positive. We divided the patients into groups based on detected WT1 expression values, illustrated overall and disease-free survival on Kaplan-Meier curves, and compared differences between each group by the logrank test. Disappearance of WT1-positivity during chemotherapy had a favorable effect on survival. Interestingly, no difference was seen between the survivals of WT1-positive subgroups that expressed moderate or high levels of WT1 mRNA. A 1-log decrease in WT1 expression without becoming negative did not affect prognosis, either. Our results suggest that defining a cut-off value for WT1-positivity, rather than just using logarithmic figures of changes in gene expression, might have prognostic use in post-induction AML patients. We encourage further, larger-scale studies.

AB - Expression of the gene Wilms tumor 1 (WT1) has been suggested as a marker of minimal residual disease in acute myeloid leukemia (AML), but literature data are not without controversy. Our aim was to assess the presence, magnitude and temporal changes of WT1 expression as prognostic factors. 60 AML patients were followed until death or the end of the 6-year observation period. Blood samples were taken at diagnosis, post-induction, during remission and in case of a relapse. Using quantitative real-time PCR, we determined WT1 expression from each sample, normalized it against the endogenous control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and classified samples as negative, moderately positive or highly positive. We divided the patients into groups based on detected WT1 expression values, illustrated overall and disease-free survival on Kaplan-Meier curves, and compared differences between each group by the logrank test. Disappearance of WT1-positivity during chemotherapy had a favorable effect on survival. Interestingly, no difference was seen between the survivals of WT1-positive subgroups that expressed moderate or high levels of WT1 mRNA. A 1-log decrease in WT1 expression without becoming negative did not affect prognosis, either. Our results suggest that defining a cut-off value for WT1-positivity, rather than just using logarithmic figures of changes in gene expression, might have prognostic use in post-induction AML patients. We encourage further, larger-scale studies.

KW - Acute myeloid leukemia

KW - Overexpression

KW - Quantitative real-time PCR

KW - WT1 gene

UR - http://www.scopus.com/inward/record.url?scp=84951573719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951573719&partnerID=8YFLogxK

U2 - 10.1007/s12253-015-0002-0

DO - 10.1007/s12253-015-0002-0

M3 - Article

C2 - 26531831

AN - SCOPUS:84951573719

VL - 22

SP - 217

EP - 221

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -